Cell-based multivariate phenotypic assays can accelerate both target-centric and phenotypic drug discovery as their rich content provides information on desired effects and possible modes of action. Growing evidence indicates that results generated from phenotypic assays are especially effective in discovering first-in-class drugs. This is why many scientists are using phenotypic approaches alongside traditional target-based methods to make new findings and to ensure the physiological relevance of their results early in the process.
This webinar features:
- Presentations on two different approaches to phenotypic screening, from running the screen to identifying hits
- A discussion on the use of high content imaging in phenotypic screening for drug discovery research
- The latest research on the application of cell-based label-free phenotypic assays for analyzing G-protein-coupled receptor (GPCR) responses
- Q&A session.
Speakers:
David L. Roman, Ph.D.
Associate Professor of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences & Experimental Therapeutics, The University of Iowa College of Pharmacy
Val J. Watts, Ph.D.
Professor of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University
Christopher Hale, Ph.D.
Scientist, Discovery Technologies, Amgen Inc.